153 related articles for article (PubMed ID: 16582019)
1. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.
Molavi B; Chen J; Mehta JL
Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H687-93. PubMed ID: 16582019
[TBL] [Abstract][Full Text] [Related]
2. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
Ren L; Liu N; Zhi H; Li Y; Li Y; Tang R; Sheng Z
Cardiovasc Diabetol; 2011 Jan; 10():10. PubMed ID: 21269478
[TBL] [Abstract][Full Text] [Related]
3. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice.
Morrison A; Yan X; Tong C; Li J
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H895-902. PubMed ID: 21666107
[TBL] [Abstract][Full Text] [Related]
4. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
Geng DF; Wu W; Jin DM; Wang JF; Wu YM
Int J Cardiol; 2006 Oct; 113(1):86-91. PubMed ID: 16891009
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Yasuda S; Kobayashi H; Iwasa M; Kawamura I; Sumi S; Narentuoya B; Yamaki T; Ushikoshi H; Nishigaki K; Nagashima K; Takemura G; Fujiwara T; Fujiwara H; Minatoguchi S
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1558-65. PubMed ID: 19286954
[TBL] [Abstract][Full Text] [Related]
6. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.
Benkirane K; Amiri F; Diep QN; El Mabrouk M; Schiffrin EL
Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H390-7. PubMed ID: 16155101
[TBL] [Abstract][Full Text] [Related]
7. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Wayman NS; Hattori Y; McDonald MC; Mota-Filipe H; Cuzzocrea S; Pisano B; Chatterjee PK; Thiemermann C
FASEB J; 2002 Jul; 16(9):1027-40. PubMed ID: 12087064
[TBL] [Abstract][Full Text] [Related]
8. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Gaikwad AB; Viswanad B; Ramarao P
Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
[TBL] [Abstract][Full Text] [Related]
9. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway.
Bulhak AA; Jung C; Ostenson CG; Lundberg JO; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H719-27. PubMed ID: 19151258
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
Zhang XJ; Xiong ZB; Tang AL; Ma H; Ma YD; Wu JG; Dong YG
Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):156-61. PubMed ID: 19566839
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.
Gao DF; Niu XL; Hao GH; Peng N; Wei J; Ning N; Wang NP
Biochem Pharmacol; 2007 Jan; 73(2):185-97. PubMed ID: 17074304
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.
Ren L; Li Y; Li Y; Tang R; Hu D; Sheng Z; Liu N
Cell Biochem Funct; 2010 Jan; 28(1):58-65. PubMed ID: 20029960
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.
Tao L; Wang Y; Gao E; Zhang H; Yuan Y; Lau WB; Chan L; Koch WJ; Ma XL
Circ Res; 2010 Feb; 106(2):409-17. PubMed ID: 19940263
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
Benkirane K; Viel EC; Amiri F; Schiffrin EL
Hypertension; 2006 Jan; 47(1):102-8. PubMed ID: 16344371
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.
Yue TL; Bao W; Gu JL; Cui J; Tao L; Ma XL; Ohlstein EH; Jucker BM
Diabetes; 2005 Feb; 54(2):554-62. PubMed ID: 15677515
[TBL] [Abstract][Full Text] [Related]
17. Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin.
Semple DJ; Bhandari S; Seymour AM
Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1275-86. PubMed ID: 22914780
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells.
Gao D; Hao G; Meng Z; Ning N; Yang G; Liu Z; Dong X; Niu X
PLoS One; 2015; 10(4):e0123724. PubMed ID: 25874449
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Khandoudi N; Delerive P; Berrebi-Bertrand I; Buckingham RE; Staels B; Bril A
Diabetes; 2002 May; 51(5):1507-14. PubMed ID: 11978649
[TBL] [Abstract][Full Text] [Related]
20. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
Hou X; Zhang Y; Shen YH; Liu T; Song S; Cui L; Bu P
Eur J Pharmacol; 2013 Sep; 715(1-3):196-203. PubMed ID: 23791613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
